X

Trial Profile

An Open-label Phase 1 Study of E7386 in Subjects With Advanced Solid Tumor Including Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Fibroma; Gastrointestinal cancer; Neuroendocrine tumours; Solid tumours
Focus Adverse reactions
Sponsors Eisai Co Ltd

Most Recent Events

15 Jan 2025 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
15 Jan 2025 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
18 Jul 2024 Planned End Date changed from 31 Mar 2025 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com